Finerenone was associated with a 16% reduction for the primary composite endpoint of cardiovascular death and total HF events compared with placebo. The Food and Drug Administration (FDA) has ...

New FINEARTS-HF (NCT04435626) data presented by Jawad Haider Butt, MD, PhD, of Glasgow Cardiovascular Research Center, University of Glasgow, at the American College of Cardiology Annual ...

Researchers validated the performance of the PREDICT-HFpEF tool in the FINEARTS-HF trial (2020-2023), which assessed the efficacy and safety of finerenone in patients with HFmrEF/HFpEF.